Focused Wealth Management Has Raised By $412,020 Its Teva Pharmaceutical Inds LTD (TEVA) Position, 9 Analysts Bullish LinkedIn (LNKD)

May 31, 2017 - By Migdalia James

Among 36 analysts covering LinkedIn (NYSE:LNKD), 9 have Buy rating, 1 Sell and 26 Hold. Therefore 25% are positive. LinkedIn had 76 analyst reports since July 28, 2015 according to SRatingsIntel. M Partners initiated the stock with “Buy” rating in Tuesday, July 28 report. The stock of LinkedIn Corp (NYSE:LNKD) earned “Neutral” rating by Wedbush on Thursday, October 1. The firm has “Buy” rating by BGC FInancial given on Wednesday, October 28. Vetr downgraded the stock to “Hold” rating in Thursday, September 17 report. The firm has “Market Underperform” rating given on Monday, June 13 by Avondale. The stock of LinkedIn Corp (NYSE:LNKD) earned “Speculative Buy” rating by ForwardView Consulting on Tuesday, February 9. Topeka Capital Markets maintained LinkedIn Corp (NYSE:LNKD) rating on Friday, February 5. Topeka Capital Markets has “Buy” rating and $225 target. The firm has “Neutral” rating given on Friday, April 29 by Wedbush. Mizuho maintained the shares of LNKD in report on Friday, April 29 with “Neutral” rating. Vetr upgraded LinkedIn Corp (NYSE:LNKD) rating on Wednesday, August 12. Vetr has “Buy” rating and $214.58 target. See LinkedIn Corp (NYSE:LNKD) latest ratings:

Focused Wealth Management Inc increased Teva Pharmaceutical Inds Ltd (TEVA) stake by 63.94% reported in 2016Q4 SEC filing. Focused Wealth Management Inc acquired 11,445 shares as Teva Pharmaceutical Inds Ltd (TEVA)’s stock declined 15.11%. The Focused Wealth Management Inc holds 29,345 shares with $1.06M value, up from 17,900 last quarter. Teva Pharmaceutical Inds Ltd now has $28.07 billion valuation. The stock declined 0.14% or $0.04 reaching $27.78 on the news. About 9.25M shares traded or 11.18% up from the average. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since May 31, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.

Focused Wealth Management Inc decreased Blackrock Debt Strat Fd Inc (DSU) stake by 99,664 shares to 59,519 valued at $675,000 in 2016Q4. It also reduced Vanguard Intl Equity Index F (VGK) stake by 206,017 shares and now owns 21,472 shares. Powershares Etf Tr Ii (BAB) was reduced too.

Among 24 analysts covering Teva Pharma (NYSE:TEVA), 12 have Buy rating, 1 Sell and 11 Hold. Therefore 50% are positive. Teva Pharma had 57 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Hold” rating by HSBC on Friday, November 4. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Neutral” rating by Mizuho on Friday, February 10. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Buy” rating by Maxim Group on Wednesday, January 4. Maxim Group downgraded it to “Hold” rating and $41.0 target in Friday, January 6 report. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Hold” rating given on Tuesday, February 28 by Argus Research. On Tuesday, July 21 the stock rating was maintained by Leerink Swann with “Outperform”. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Buy” rating given on Monday, July 18 by HSBC. The rating was maintained by Jefferies with “Buy” on Thursday, July 14. Argus Research maintained it with “Buy” rating and $82 target in Tuesday, July 28 report. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Outperform” rating by RBC Capital Markets on Wednesday, July 29.

It closed at $195.96 lastly. It is down 0.00% since May 31, 2016 and is . It has underperformed by 16.70% the S&P500.